Skip to search formSkip to main contentSkip to account menu

LCI699

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Efficacy and safety of LCI 699 for hypertension : a meta-analysis of randomized controlled trials and systematic review
296 Abstract. – OBJECTIVE: This study reviews the available data from randomized controlled trials on efficacy and safety of… 
2015
2015
Effects of osilodrostat (LCI699) on cytochrome P450 enzymes in healthy volunteers indicates a low drug-drug interaction potential
2015
2015
Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design
2014
2014
Medical management of functioning pituitary adenoma: an update.
The treatment of functioning pituitary adenoma (FPA) must achieve endocrinological remission as well as tumor size reduction. The… 
2012
2012
Identification de nouvelles options thérapeutiques et diagnostiques dans l'hyperaldostéronisme primaire
L’hyperaldosteronisme primaire [HAP] resulte d’une hypersecretion d’aldosterone d’origine surrenale. La comprehension de la… 
2012
2012
Letter by Keidar and Gamliel-Lazarovich
inwhich the authors tested the effect of a novel aldosterone synthaseinhibitor, LCI699, for treatment of primary hypertension. An… 
2010
2010
HORMONAL EFFECTS OF THE NEW DIRECT ALDOSTERONE SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C.06
Objective: Aldosterone synthase inhibition with LCI699 is a new therapeutic option aimed at decreasing hormone concentrations in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)